SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential

Yu Feng Tian, Tzu Ju Chen, Ching Yih Lin, Li Tzong Chen, Li Ching Lin, Chung Hsi Hsing, Sung Wei Lee, Ming Jen Sheu, Hao Hsien Lee, Yow Ling Shiue, Hsuan Ying Huang, Hsin Yi Pan, Chien Feng Li, Shang Hung Chen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase. Overexpression of SKP2 was found in various human cancers, including colorectal cancers, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention in rectal cancers is unknown. This study examined the correlation of SKP2 expression in the prognosis of rectal cancer patients and the viability of colorectal cancer cells treated with CRT. SKP2 immunoexpression was retrospectively assessed in pretreatment biopsies of 172 rectal cancer patients treated with neoadjuvant CRT followed by surgery. Results were correlated with clinicopathological features, therapeutic responses, and patient survival. Pharmacologic assays were used to evaluate the therapeutic relevance of Bortezomib in two colorectal cancer cell lines (HT-29 and SW480). High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for Cancer Control stage (p = 0.002), and a lower-degree tumor regression grade (p <0.001). Moreover, high expression of SKP2 (p = 0.027, hazard ratio 3.21) was an independent prognostic factor for local recurrence-free survival. In vitro, Bortezomib downregulated SKP2 expression, induced caspase activation, and decreased the viability of colorectal cancer cells with or without a combination with fluorouracil. Bortezomib also promoted caspase activation and gamma-H2AX formation in colorectal cancer cells concurrently treated with CRT. High expression of SKP2 was associated with a poor therapeutic response and adverse outcomes in rectal cancer patients treated with neoadjuvant CRT. In the presence of chemotherapy with or without radiotherapy, the promoted sensitivity of colorectal cancer cells to Bortezomib with an SKP2-repressing effect indicated that it is a potential therapeutic target.

Original languageEnglish
Pages (from-to)1107-1117
Number of pages11
JournalTumor Biology
Volume34
Issue number2
DOIs
Publication statusPublished - Apr 2013
Externally publishedYes

Fingerprint

S-Phase Kinase-Associated Proteins
Chemoradiotherapy
Rectal Neoplasms
Colorectal Neoplasms
Therapeutics
Caspases
Neoplasms
Ubiquitin-Protein Ligases
Survival
Oncogene Proteins
Fluorouracil
Radiotherapy
Down-Regulation

Keywords

  • Neoadjuvant chemoradiotherapy
  • Rectal cancer
  • SKP2

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. / Tian, Yu Feng; Chen, Tzu Ju; Lin, Ching Yih; Chen, Li Tzong; Lin, Li Ching; Hsing, Chung Hsi; Lee, Sung Wei; Sheu, Ming Jen; Lee, Hao Hsien; Shiue, Yow Ling; Huang, Hsuan Ying; Pan, Hsin Yi; Li, Chien Feng; Chen, Shang Hung.

In: Tumor Biology, Vol. 34, No. 2, 04.2013, p. 1107-1117.

Research output: Contribution to journalArticle

Tian, YF, Chen, TJ, Lin, CY, Chen, LT, Lin, LC, Hsing, CH, Lee, SW, Sheu, MJ, Lee, HH, Shiue, YL, Huang, HY, Pan, HY, Li, CF & Chen, SH 2013, 'SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential', Tumor Biology, vol. 34, no. 2, pp. 1107-1117. https://doi.org/10.1007/s13277-013-0652-z
Tian, Yu Feng ; Chen, Tzu Ju ; Lin, Ching Yih ; Chen, Li Tzong ; Lin, Li Ching ; Hsing, Chung Hsi ; Lee, Sung Wei ; Sheu, Ming Jen ; Lee, Hao Hsien ; Shiue, Yow Ling ; Huang, Hsuan Ying ; Pan, Hsin Yi ; Li, Chien Feng ; Chen, Shang Hung. / SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. In: Tumor Biology. 2013 ; Vol. 34, No. 2. pp. 1107-1117.
@article{3b05ca59dcfd4acfa58d942e3589c08d,
title = "SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential",
abstract = "The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase. Overexpression of SKP2 was found in various human cancers, including colorectal cancers, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention in rectal cancers is unknown. This study examined the correlation of SKP2 expression in the prognosis of rectal cancer patients and the viability of colorectal cancer cells treated with CRT. SKP2 immunoexpression was retrospectively assessed in pretreatment biopsies of 172 rectal cancer patients treated with neoadjuvant CRT followed by surgery. Results were correlated with clinicopathological features, therapeutic responses, and patient survival. Pharmacologic assays were used to evaluate the therapeutic relevance of Bortezomib in two colorectal cancer cell lines (HT-29 and SW480). High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for Cancer Control stage (p = 0.002), and a lower-degree tumor regression grade (p <0.001). Moreover, high expression of SKP2 (p = 0.027, hazard ratio 3.21) was an independent prognostic factor for local recurrence-free survival. In vitro, Bortezomib downregulated SKP2 expression, induced caspase activation, and decreased the viability of colorectal cancer cells with or without a combination with fluorouracil. Bortezomib also promoted caspase activation and gamma-H2AX formation in colorectal cancer cells concurrently treated with CRT. High expression of SKP2 was associated with a poor therapeutic response and adverse outcomes in rectal cancer patients treated with neoadjuvant CRT. In the presence of chemotherapy with or without radiotherapy, the promoted sensitivity of colorectal cancer cells to Bortezomib with an SKP2-repressing effect indicated that it is a potential therapeutic target.",
keywords = "Neoadjuvant chemoradiotherapy, Rectal cancer, SKP2",
author = "Tian, {Yu Feng} and Chen, {Tzu Ju} and Lin, {Ching Yih} and Chen, {Li Tzong} and Lin, {Li Ching} and Hsing, {Chung Hsi} and Lee, {Sung Wei} and Sheu, {Ming Jen} and Lee, {Hao Hsien} and Shiue, {Yow Ling} and Huang, {Hsuan Ying} and Pan, {Hsin Yi} and Li, {Chien Feng} and Chen, {Shang Hung}",
year = "2013",
month = "4",
doi = "10.1007/s13277-013-0652-z",
language = "English",
volume = "34",
pages = "1107--1117",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential

AU - Tian, Yu Feng

AU - Chen, Tzu Ju

AU - Lin, Ching Yih

AU - Chen, Li Tzong

AU - Lin, Li Ching

AU - Hsing, Chung Hsi

AU - Lee, Sung Wei

AU - Sheu, Ming Jen

AU - Lee, Hao Hsien

AU - Shiue, Yow Ling

AU - Huang, Hsuan Ying

AU - Pan, Hsin Yi

AU - Li, Chien Feng

AU - Chen, Shang Hung

PY - 2013/4

Y1 - 2013/4

N2 - The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase. Overexpression of SKP2 was found in various human cancers, including colorectal cancers, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention in rectal cancers is unknown. This study examined the correlation of SKP2 expression in the prognosis of rectal cancer patients and the viability of colorectal cancer cells treated with CRT. SKP2 immunoexpression was retrospectively assessed in pretreatment biopsies of 172 rectal cancer patients treated with neoadjuvant CRT followed by surgery. Results were correlated with clinicopathological features, therapeutic responses, and patient survival. Pharmacologic assays were used to evaluate the therapeutic relevance of Bortezomib in two colorectal cancer cell lines (HT-29 and SW480). High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for Cancer Control stage (p = 0.002), and a lower-degree tumor regression grade (p <0.001). Moreover, high expression of SKP2 (p = 0.027, hazard ratio 3.21) was an independent prognostic factor for local recurrence-free survival. In vitro, Bortezomib downregulated SKP2 expression, induced caspase activation, and decreased the viability of colorectal cancer cells with or without a combination with fluorouracil. Bortezomib also promoted caspase activation and gamma-H2AX formation in colorectal cancer cells concurrently treated with CRT. High expression of SKP2 was associated with a poor therapeutic response and adverse outcomes in rectal cancer patients treated with neoadjuvant CRT. In the presence of chemotherapy with or without radiotherapy, the promoted sensitivity of colorectal cancer cells to Bortezomib with an SKP2-repressing effect indicated that it is a potential therapeutic target.

AB - The S-phase kinase-associated protein 2 (SKP2) oncoprotein is an E3 ubiquitin ligase. Overexpression of SKP2 was found in various human cancers, including colorectal cancers, but its potential role as a prognostic marker after neoadjuvant chemoradiotherapy (CRT) and for therapeutic intervention in rectal cancers is unknown. This study examined the correlation of SKP2 expression in the prognosis of rectal cancer patients and the viability of colorectal cancer cells treated with CRT. SKP2 immunoexpression was retrospectively assessed in pretreatment biopsies of 172 rectal cancer patients treated with neoadjuvant CRT followed by surgery. Results were correlated with clinicopathological features, therapeutic responses, and patient survival. Pharmacologic assays were used to evaluate the therapeutic relevance of Bortezomib in two colorectal cancer cell lines (HT-29 and SW480). High expression of SKP2 was correlated with the advanced Post-Tx nodal status (p = 0.002), Post-Tx International Union for Cancer Control stage (p = 0.002), and a lower-degree tumor regression grade (p <0.001). Moreover, high expression of SKP2 (p = 0.027, hazard ratio 3.21) was an independent prognostic factor for local recurrence-free survival. In vitro, Bortezomib downregulated SKP2 expression, induced caspase activation, and decreased the viability of colorectal cancer cells with or without a combination with fluorouracil. Bortezomib also promoted caspase activation and gamma-H2AX formation in colorectal cancer cells concurrently treated with CRT. High expression of SKP2 was associated with a poor therapeutic response and adverse outcomes in rectal cancer patients treated with neoadjuvant CRT. In the presence of chemotherapy with or without radiotherapy, the promoted sensitivity of colorectal cancer cells to Bortezomib with an SKP2-repressing effect indicated that it is a potential therapeutic target.

KW - Neoadjuvant chemoradiotherapy

KW - Rectal cancer

KW - SKP2

UR - http://www.scopus.com/inward/record.url?scp=84877133584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877133584&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-0652-z

DO - 10.1007/s13277-013-0652-z

M3 - Article

VL - 34

SP - 1107

EP - 1117

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 2

ER -